Meeting
2016 Genitourinary Cancers Symposium
Real world chart review of adverse event management in patients taking tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC) by line of therapy (LoT).
Authors
Sandhya Srinivas
Stanford University Medical Center, Stanford, CA
Sandhya Srinivas , Dara Stein , Dana Y Teltsch , Sunning Tao , Krishnan Ramaswamy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 521)
DOI
10.1200/jco.2016.34.2_suppl.521
Abstract #
521
Poster Bd #
E4
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): A single-institution experience.
First Author: Marc Ryan Matrana
Poster
2023 ASCO Genitourinary Cancers Symposium
Estimated cost of adverse event (AE) management for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with a VEGFR TKI.
First Author: Jeffrey Thomas Yorio
Poster
2020 Genitourinary Cancers Symposium
A randomized, double-blinded clinical trial of royal jelly intake for anticancer effects and suppressing adverse events in renal cell carcinoma patients treated with tyrosine kinase inhibitors.
First Author: Yasuyoshi Miyata
Poster
2018 Genitourinary Cancers Symposium
A FavorAx study of axitinib in favorable risk patients with metastatic renal cell carcinoma.
First Author: Ilya Tsimafeyeu